(Reuters) - Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on ...

Veranex, a global provider of product development and contract research services, today introduced the industry’s first ...

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

Johnson & Johnson (NYSE: JNJ) shares ticked up before hours today on second-quarter results that came in ahead of the ...

Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara ...

Affected Alaris products may have been serviced with previously recalled bezel kit assemblies. BD in 2019 recalled those kit ...

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

Medical technology has been on the up for many years, and professionals and experts in Australia have been making strides in innovation over the last decade.

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

Steris (STE) stock and Solventum (SOLV) stock is upgraded, while RxSight (RXST) stock is downgraded at Morgan Stanley on valuations. Read more here.

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...